GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
1.940 USD   -0.51%
05/17Gritstone to Participate in H.C. Wainwright Global Investment Conference
AQ
05/11TRANSCRIPT : Gritstone bio, Inc. - Shareholder/Analyst Call
CI
05/09HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GRITSTONE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

01/04/2022 | 05:25pm EDT

Item 8.01 Other Events.

On January 4, 2022, Gritstone bio, Inc. (the "Company" or "Gritstone") announced positive clinical results from the first cohort of its Phase 1 Study (CORAL-BOOST) evaluating a T cell-enhanced self-amplifying mRNA (samRNA) vaccine against COVID-19. A copy of the press release with the foregoing announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Spokespersons of Gritstone plan to present the information in the presentation slides attached hereto as Exhibit 99.2 at various upcoming investor and analyst meetings previously announced by the Company. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.




Exhibit
  No.       Description

99.1          Press Release dated January 4, 2022

99.2          Presentation Slides January 2022

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about GRITSTONE BIO, INC.
05/17Gritstone to Participate in H.C. Wainwright Global Investment Conference
AQ
05/11TRANSCRIPT : Gritstone bio, Inc. - Shareholder/Analyst Call
CI
05/09HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating
MT
05/06CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Busin..
GL
05/06CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Busin..
GL
05/05GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/05Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $7.2M, vs. Street Est of $4.21M
MT
05/05Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
AQ
05/05Gritstone bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Op..
GL
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations